arGEN-X (Netherlands) a preclinical-stage biopharmaceutical company focused on a monoclonal antibody platform for autoimmunity, inflammation and oncology, closed a $37M Series B financing. Participants include Orbimed, Seventure, Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, BioGeneration Ventures, Erasmus MC Biomedical Fund, Thuja Capital Healthcare and VIB.

Syntaxin (United Kingdom) a preclinical-stage biopharmaceutical company focusing on targeted secretion inhibitors for the potential treatment of pain, endocrine disease and cancer, closed a $28.3M Series C financing. Participants include Lundbeckfond Ventures, Ipsen, Seventure Partners, Abingworth, SROne, Life Science Partners, Johnson & Johnson Development Corp and Quest for Growth.

Okairos (Switzerland) a clinical-stage biopharmaceutical company developing T-cell vaccines against infectious diseases such as malaria, HIV, hepatitis C and influenza, closed a $20.8M Series B financing. Participants include Versant Ventures, Boehringer Ingelheim Venture Fund, BioMedPartners, Life Science Partners and Novartis Venture Fund.

Probiodrug (Germany) a clinical-stage small molecule biopharmaceutical company focused upon Alzheimer’s and inflammation diseases, closed a $54M Series B financing. Participants include BB Biotech, Edmond de Rothschild Investment Partners, Life Science Partners, Biogen Idec New Ventures, HBM Bioventures and TVM Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Kreatech Diagnostics (Netherlands) a commercial-stage molecular diagnostics company focused on DNA FISH probes and nucleic acid labeling technologies, closed a $2.7M Series B financing. Participants include Alafi Capital and Life Science Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb